Page 96 - Strategies for non-invasive managementof high-grade cervical intraepithelial neoplasia - prognostic biomarkers and immunotherapy Margot Maria Koeneman

Chapter 4
References
1. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000;92(9):690-8.
2. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9(5):425-34.
3. Trimble CL, Piantadosi S, Gravitt P, Ronnett B, Pizer E, Elko A, et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res. 2005;11(13):4717-23.
4. Ovestad IT, Gudlaugsson E, Skaland I, Malpica A, Munk AC, Janssen EA, et al. The impact of epithelial biomarkers, local immune response and human papillomavirus genotype in the regression of cervical intraepithelial neoplasia grades 2-3. J Clin Pathol. 2011;64(4):303-7.
5. Munk AC, Gudlaugsson E, Ovestad IT, Lovslett K, Fiane B, Hidle B, et al. Interaction of epithelial biomarkers, local immune response and condom use in cervical intraepithelial neoplasia 2-3 regression. Gynecol Oncol. 2012;127(3):489-94.
6. Grimm C, Polterauer S, Natter C, Rahhal J, Hefler L, Tempfer CB, et al. Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial. Obstet Gynecol. 2012;120(1):152-9.
7. Barken SS, Rebolj M, Andersen ES, Lynge E. Frequency of cervical intraepithelial neoplasia treatment in a well-screened population. Int J Cancer. 2012;130(10):2438-44.
8. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550-60.
9. Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev. 2012;25(2):215-22.
10. Litjens RJ, Hopman AH, van de Vijver KK, Ramaekers FC, Kruitwagen RF, Kruse AJ. Molecular biomarkers in cervical cancer diagnosis: a critical appraisal. Expert Opin Med Diagn. 2013;7(4):365-77.
11. Koeneman MM, Kruitwagen RF, Nijman HW, Slangen BF, Van Gorp T, Kruse AJ. Natural history of high-grade cervical intraepithelial neoplasia: a review of prognostic biomarkers. Expert Rev Mol Diagn. 2015;15(4):527-46.
12. Thomas LK, Bermejo JL, Vinokurova S, Jensen K, Bierkens M, Steenbergen R, et al. Chromosomal gains and losses in human papillomavirus-associated neoplasia of the lower genital tract - a systematic review and meta-analysis. Eur J Cancer. 2014;50(1):85-98.
13. Seppo A, Jalali GR, Babkowski R, Symiakaki H, Rodolakis A, Tafas T, et al. Gain of 3q26: a genetic marker in low-grade squamous intraepithelial lesions (LSIL) of the uterine cervix. Gynecol Oncol. 2009;114(1):80-3.
14. Earley A, Lamont JL, Dahabreh IJ, Cowan J, Feldman S, Uhlig K. Fluorescence in situ hybridization testing for the diagnosis of high-grade cervical abnormalities: a systematic review. J Low Genit Tract Dis. 2014;18(3):218-27.
15. Hopman AH, Theelen W, Hommelberg PP, Kamps MA, Herrington CS, Morrison LE, et al. Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC
94